# STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

> **NCT00623623** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1899 (actual)

## Conditions studied

- Myocardial Infarction

## Interventions

- **PROCEDURE:** primary PCI
- **DRUG:** enoxaparin
- **PROCEDURE:** catheterisation
- **DRUG:** tenecteplase
- **DRUG:** clopidogrel

## Key facts

- **NCT ID:** NCT00623623
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-01
- **Primary completion:** 2012-09-01
- **Final completion:** 2012-09-01
- **Target enrollment:** 1899 (ACTUAL)
- **Last updated:** 2019-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00623623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00623623, "STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00623623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*